Rapport ‘fully prepared’ to launch seizure drug solo, CEO says

In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.

By Jacob Bell • June 12, 2026

Summit pulls $500M share sale a day after announcing it

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

By Jonathan Gardner • June 11, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

By BioPharma Dive staff • June 11, 2026

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

By Delilah Alvarado • June 10, 2026

Parabilis sets a record with a $670M biotech IPO

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined. 

By Gwendolyn Wu • June 10, 2026

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

By BioPharma Dive staff • June 10, 2026

Amid a flurry of biotech deals, China looks to keep innovation at home

The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.

By Kelly Bilodeau • June 10, 2026

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

By Gwendolyn Wu • June 9, 2026

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

By Gwendolyn Wu • June 8, 2026

Tango data add to growing momentum for pancreatic cancer drugs

A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

By Jonathan Gardner • June 8, 2026

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B

The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

By Gwendolyn Wu • June 8, 2026

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

By Kelly Bilodeau • June 5, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

By Kristin Jensen • June 4, 2026

An ADC specialist sinks on safety concerns for blood cancer drug

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”

By Delilah Alvarado • June 4, 2026

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

By BioPharma Dive staff • June 4, 2026

A Spanish biotech banks $87M to make differentiated ADCs

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

By Gwendolyn Wu • June 4, 2026

Legend surges on early data for ‘in vivo’ lymphoma cell therapy

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

By Jonathan Gardner • June 3, 2026

House bill aims to crack down on China biotech deals

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.

By Kristin Jensen • June 3, 2026

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

By BioPharma Dive staff • June 3, 2026

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

By Jacob Bell • June 2, 2026

RallyBio tries again for reverse merger, this time with Avenzo

It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.

By Gwendolyn Wu • June 1, 2026

Akeso, Summit drug extends survival in closely watched lung cancer trial

Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.

By Jonathan Gardner • Updated June 1, 2026

‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

By Jonathan Gardner • May 31, 2026

Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.

By Jacob Bell • May 29, 2026

Allogene CEO to step down; Agios drug fails key test

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

By Ben Fidler • May 29, 2026